

Original Research

# The Atherogenic Index of Plasma is a Predictor for Chronic Total Occlusion and Coronary Collateral Circulation Formation in CTOs Patients

Ya Li<sup>1,†</sup>, Yujia Feng<sup>1,†</sup>, Ya Zhong<sup>2,†</sup>, Shu Li<sup>3</sup>, Jiesheng Lin<sup>4</sup>, Peng Fang<sup>5</sup>, Jing Wan<sup>1,\*</sup>, Min Zhao<sup>6,\*</sup><sup>1</sup>Department of Cardiology, Zhongnan Hospital of Wuhan University, 430071 Wuhan, Hubei, China<sup>2</sup>Department of Geratology, Zhongnan Hospital of Wuhan University, 430071 Wuhan, Hubei, China<sup>3</sup>Department of Intensive Care Unit, Zhongnan Hospital of Wuhan University, 430071 Wuhan, Hubei, China<sup>4</sup>Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Munich, Germany<sup>5</sup>Department of Cardiology, Huangshi 5th Hospital, 435005 Huangshi, Hubei, China<sup>6</sup>Demonstration Center for Experimental Basic Medicine Education, Taikang Medical School (School of Basic Medical Sciences), Wuhan University, 430071 Wuhan, Hubei, China\*Correspondence: [wanjing\\_zn@163.com](mailto:wanjing_zn@163.com) (Jing Wan); [zhaomin28@163.com](mailto:zhaomin28@163.com) (Min Zhao)

†These authors contributed equally.

Academic Editor: Carmela Rita Balistreri

Submitted: 5 January 2023 Revised: 17 July 2023 Accepted: 21 July 2023 Published: 23 October 2023

## Abstract

**Background:** The atherogenic index of plasma (AIP), determined by the logarithmic transformation of the ratio of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C), was found to be a marker of cardiovascular disease. We sought to investigate the correlation between the atherogenic AIP and coronary collateral circulation (CCC) formation in chronic total occlusive (CTOs) patients. **Methods:** This retrospective cohort study included 665 non-CTOs and 345 CTOs patients. CTOs were divided into 206 CCC poor formation patients and 139 CCC good formation patients according to the Cohen-Rentrop grade. Spearman correlation analysis was carried out to obtain the relationship between AIP and the Rentrop grade. We used multivariate logistic regression analysis to assess CTOs and CCC poor formation risk factors. Receiver operating characteristic (ROC) curves were used to determine the optimal threshold for AIP to predict CTOs and CCC poor formation. The predicted increment of AIP on CTOs and CCC poor formation was evaluated by calculating the Net Reclassification Index (NRI) and the Integrated Discriminant Index (IDI). **Results:** AIP in CTOs was significantly elevated compared to non-CTOs patients [(1.55 (1.02, 2.59)) vs (1.26 (0.82, 1.90)),  $p < 0.001$ ] AIP in the CCC poor formation group was significantly higher than that in the CCC good formation group [(1.73 (1.12, 2.90)) vs (1.37 (0.84, 2.13)),  $p = 0.002$ ]. There was a negative correlation between AIP and the Rentrop grade ( $r = -0.145$ ,  $p = 0.007$ ). The results of multivariate logistic regression revealed that AIP was an independent predictor of CTOs (OR = 4.371, 95% CI: 2.436–7.844,  $p < 0.001$ ) and CCC poor formation (OR = 3.749, 95% CI: 1.628–8.635,  $p = 0.002$ ). In the ROC analysis, the area under the curve of AIP for identifying CTOs and CCC poor formation was 0.596 (OR = 3.680, 95% CI: 1.490–9.090,  $p = 0.005$ ) and 0.597 (95% CI: 0.535–0.658,  $p = 0.002$ ), respectively. **Conclusions:** Contrary to previous research, we found that AIP is a moderate but not powerful indicator for detecting both CTO patients and poor CCC formation.

**Keywords:** atherogenic index of plasma; coronary collateral circulation; chronic total occlusive disease; coronary angiography; diagnosis

## 1. Introduction

Chronic total occlusions (CTOs) are a common finding in patients with coronary artery disease (CAD), with a reported prevalence of approximately one-third in this patient population. This is a major global health concern in the field of cardiovascular medicine [1]. CTOs are frequently seen during coronary angiography and involve coronary artery complete occlusion for more than 3 months. Studies have indicated that the presence of CTOs is associated with a higher incidence of major adverse cardiovascular events (MACEs). This highlights the importance of identifying and treating CTOs in patients with CAD to reduce the risk of adverse cardiovascular outcomes [2]. Coronary collateral circulation (CCC) is an arterial anastomosis net-

work that forms a natural bypass through arteriogenesis or lumen expansion when there is insufficient blood flow in the distal myocardium when coronary artery occlusion occurs [3]. A reduction in mortality and an improvement in cardiac function is associated with the presence of well-formed collaterals, which has cardioprotective effects on ischemic myocardium [4,5]. Therefore, it is necessary to predict and evaluate the formation of CCC in clinical practice. However, the current methods to evaluate CCC such as the Collateral Flow Index (CFI) and intracoronary electrocardiogram are relatively complex and expensive. Therefore, there is a need for a simple and cost-effective method to effectively predict or evaluate the formation of CCC in CTO patients.



The atherogenic index of plasma (AIP), determined by the logarithmic transformation of the ratio of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C), has been identified as a potential marker of cardiovascular disease. Studies have shown that AIP is associated with both the onset of CAD and the severity of coronary syndromes [6]. According to a recent study, there is a correlation between AIP levels and the severity of CTO. This suggests that AIP may be a useful biomarker for predicting the occurrence of CTO in patients with CAD [2]. Previous research has suggested that AIP levels may be an independent predictor of the complexity of CTO. This highlights the potential value of AIP as a biomarker for predicting not only the occurrence of CTO, but also their severity and complexity. In addition to the Japanese Multicenter CTO Registry (J-CTO) score, AIP may be associated with the number and length of stents used after successful revascularization [7]. However, the relationship between AIP and CTO and CCC formation has not been well studied. Therefore, we investigated the relationship between AIP and CTO as well as CCC formation to determine the effectiveness of AIP in the prediction and prognostic assessment of CTO patients in clinical practice.

## 2. Methods

### 2.1 Study Population

Between January 2013 and September 2018, patients who underwent coronary angiography in the Department of Cardiology, Zhongnan Hospital of Wuhan University in whom the coronary angiography showed a 90% stenosis in at least one branch of the three main coronary arteries (left anterior descending artery (LAD), left circumflex artery (LCA), and right coronary artery (RCA)) were consecutively enrolled [8]. CTO was defined as complete coronary artery occlusion due to thrombosis or atherosclerosis, with a duration of occlusion that lasted more than three months.

Exclusion criteria: Previous cardiovascular disease within three months (acute myocardial infarction, coronary stent placement or coronary artery bypass graft, heart failure), cardiomyopathy, congenital coronary arterial malformation or other severe diseases (liver and kidney failure, thyroid dysfunction) and patients taking lipid-lowering drugs for more than three months.

We followed the 2007 STROBE statement for reporting of observational studies [9].

### 2.2 Coronary Collateral Circulation Assessment and Grouping

Coronary angiography was performed by two interventional experts using the Judkin method by the radial or femoral approach. The Cohen-Rentrop criterion was used to evaluate CCC formation [10]: Grade 0, without any filling of the collateral arteries; Grade 1, the side branches of the occluded artery can be filled but the contrast agent can-

not reach the epicardial vessel; Grade 2, partial filling of epicardial vessels; and Grade 3, epicardial vessels are completely filled. Based on the angiography results, the participants were divided into a CTOs group and a non-CTOs group. In addition, patients with CTO were separated into the CCC poor formation group (Rentrop Grade 0–1) and the CCC good formation group (Rentrop Grade 2–3).

### 2.3 Laboratory Measurements

Venous blood was obtained from patients who had fasted for more than 10 hours. Blood lipids were measured using an automated biochemical analyzer (Beckman Coulter, AU5800, Brea, CA, USA) and an enzymatic reaction method. TG/HDL was calculated as the ratio of serum TG (mmol/L) to serum HDL-C (mmol/L), and AIP was defined as the logarithm of the ratio of TG/HDL-C.

### 2.4 Statistical Analysis


The Kolmogorov–Smirnov test was used to test the normality of data distribution. Continuous data are shown as the mean  $\pm$  SD for normal distribution and medians (interquartile ranges) for data with a non-normal distribution. Student's *t*-test and Mann–Whitney U-test were used to identify differences between the two groups, respectively. Categorical variables were expressed as percentages and compared using the  $\chi^2$ -test. Categories of the Rentrop grades were compared using one-way analysis of variance (ANOVA). We used Spearman's correlation analysis to describe the correlation between AIP and the Rentrop grade. Multivariate binary logistic regressions were used to estimate the association of AIP with prevalent CTOs (yes or no) and CCC formation (good or poor). Before performing multivariate binary logistic regression analysis, collinearity diagnosis was performed on the included variables. Variables with tolerance  $<0.1$  or variance inflation factor (VIF)  $>10$  were excluded. Receiver operating characteristic (ROC) curves were used to assess the predictive ability of AIP for CTOs and CCC poor formation. The statistical analyses were performed using IBM SPSS 23.0 software (IBM Corp, Armonk, NY, USA). In addition, we also used R software version 4.0.2 (R development Core Team, Vienna, Austria, <https://www.R-project.org>) to calculate the net reclassification index (NRI) and the integrated discrimination index (IDI) to better evaluate the predicted incremental value of AIP. In accordance with previous studies, we considered setting the threshold as B/2, B, 2B according to the incidence of CTO and poor CCC formation (B stands for incidence) [11–19], and divided patients into four risk groups. The results are represented by 95% confidence intervals (CI). A  $p < 0.05$  means represented statistical significance.

## 3. Results

### 3.1 Basic Clinical Information and Characteristics of Patients

A total of 1412 patients who underwent coronary angiography in the Department of Cardiology, Zhongnan

Hospital of Wuhan University were consecutively enrolled (Fig. 1). 402 patients who met the exclusion criteria were excluded. In total, 1010 patients were enrolled in the study, of whom 665 were non-CTO patients and 345 were CTO patients. Among the CTO patients, 139 patients were assigned to the good CCC formation group and 206 patients were assigned to the poor CCC formation group. Table 1 shows that 665 non-CTOs patients and 345 CTOs patients were included in this study. Patients in the CTOs group were older, more likely to be male and to have a history of smoking, diabetes, and hypertension, and a higher Lp(a) and AIP, but lower HDL levels.



**Fig. 1. Flowchart of the cohort patients.** LAD, left anterior descending artery; LCA, left circumflex artery; RCA, right coronary artery; AMI, acute myocardial infarction; CABG, coronary artery bypass graft; HF, heart failure; CTO, chronic total occlusive; CCC, coronary collateral circulation. <sup>#</sup>Coronary artery stenosis is assessed visually by coronary angiography.

### 3.2 Clinical Baseline and Characteristics of CTOs Patients

According to the Cohen-Rentrop criteria and the results of the CCC formation evaluation, CTOs patients were divided into good and poor CCC groups, and AIP was compared between these two groups. Table 2 showed that the CCC poor formation group had a higher AIP ( $(0.14 \pm 0.30)$  vs  $(0.26 \pm 0.31)$ ) level. The proportion of multivessel lesions in the CCC good formation group was higher, suggesting that multivessel lesions may contribute to the formation of CCC.

### 3.3 Correlation between AIP and Rentrop Grade

Spearman's correlation analysis was carried out to obtain the relationship between AIP and the Rentrop grade.

The results showed that AIP ( $r = -0.145$ ,  $p = 0.007$ ) was negatively correlated with Rentrop grade. The AIP in Rentrop 3 ( $1.22$  ( $0.8$ ,  $1.94$ )) and Rentrop 2 ( $1.53$  ( $0.89$ ,  $2.36$ )) were significantly lower than Rentrop 0 ( $1.65$  ( $1.12$ ,  $2.9$ )) and Rentrop 1 ( $1.97$  ( $1.14$ ,  $2.85$ )). The AIP between Rentrop 3 and Rentrop 2 ( $p = 0.269$ ), Rentrop 0 and Rentrop 1 ( $p = 0.351$ ) showed no significant differences.

### 3.4 Analysis of Risk Factors for CTOs and CCC Formation

The CTOs (yes or no) and CCC formation (good or poor) were used as the dependent variables. Variables with a univariate relationship with outcome and clinical relevance were included in multivariate models to reveal potential risk factors for CTO and CCC. Since the tolerance of TG and HDL-C were both  $<0.1$ , these two variables were not included in the final multivariate binary logistic analysis. After adjusting traditional cardiovascular risk factors (age, gender, smoking, diabetes, and hypertension) and plasma lipid parameters (TC, LDL-C, Lp(a)), AIP was significantly positively associated with a higher prevalence of CTOs (OR = 4.371, 95% CI: 2.436–7.844) (Table 3). In the comparison between the good CCC formation group and the poor CCC formation group, after adjusting traditional cardiovascular risk factors (age, gender, smoking, diabetes, and hypertension), plasma lipid parameters (TC, LDL-C, Lp(a)) and multivessel disease, AIP was significantly positively associated with CCC poor formation (OR = 3.680, 95% CI: 1.490–9.090) (Table 4). The higher the AIP, the more patients tended to have CTOs and poor CCC formation.

### 3.5 ROC Curve Analysis of the AIP in CTOs and CCC Poor Formation

After ROC analysis, the area under the curve of CTOs and CCCs detected by AIP was 0.596 (95% CI: 0.559–0.633,  $p < 0.001$ ) and 0.597 (95% CI: 0.535–0.658,  $p = 0.002$ ), respectively. The optimal cut-off point for CTOs was 0.28 (Youden index 0.153), with 40.6% sensitivity and 74.7% specificity (Fig. 2), while the optimal cut-off point for CCC poor formation was 0.12, with 92.2% sensitivity and 19.4% specificity (Fig. 3).

### 3.6 Evaluate the Predicted Incremental Value of AIP for CTOs and CCC Poor Formation


We calculated the net reclassification index (NRI) and integrated discrimination index (IDI) to evaluate the predicted increment of AIP on CTOs and CCC poor formation. We constructed a standard model using the risk factors in the above analysis that may be associated with CTOs and CCC poor formation (i.e., age, gender, smoking, diabetes, hypertension for CTOs, and for CCC poor formation, multivessel coronary disease is added). Adding AIP to the standard model forms a new model. Based on previous research [11–19], we set the cut-off point for CTOs as 0.2, 0.4, 0.8 and the cut-off point for CCC poor formation was 0.25 and 0.5. The final results suggest that the NRI for predicting CTO lesions and poor CCC formation are 0.066

**Table 1. Basic clinical characteristics of the study participants.**

| Variables        | non-CTOs group (n = 665) | CTOs group (n = 345)   | p value             |
|------------------|--------------------------|------------------------|---------------------|
| Age              | 58.51 ± 11.00            | 62.20 ± 11.61          | <0.001 <sup>1</sup> |
| Gender (men (%)) | 353 (55.2)               | 286 (82.9)             | <0.001 <sup>1</sup> |
| Smoking          | 138 (20.8)               | 165 (47.8)             | <0.001 <sup>1</sup> |
| Diabetes         | 80 (12.0)                | 99 (28.7)              | <0.001 <sup>1</sup> |
| Hypertension     | 295 (58.2)               | 212 (61.4)             | <0.001 <sup>1</sup> |
| TC (mmol/L)      | 4.46 ± 1.06              | 4.87 ± 1.04            | 0.838               |
| TG (mmol/L)      | 1.45 (1.01, 2.07)        | 1.51 (1.06, 2.24)      | 0.081               |
| HDL (mmol/L)     | 1.81 ± 0.30              | 1.01 ± 0.27            | <0.001 <sup>1</sup> |
| LDL (mmol/L)     | 2.68 ± 0.86              | 2.79 ± 0.80            | 0.052               |
| LP(a) (mg/L)     | 109.95 (53.53, 210.63)   | 127.70 (65.40, 243.65) | 0.011 <sup>2</sup>  |
| AIP              | 1.26 (0.82, 1.90)        | 1.55 (1.02, 2.59)      | <0.001 <sup>1</sup> |

CTOs, chronic total occlusions; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LP(a), Lipoprotein(a); AIP, atherogenic index of plasma.

Note: <sup>1</sup> $p < 0.01$ , <sup>2</sup> $p < 0.05$ .




**Fig. 2. AIP prediction of CTOs with ROC curves.** AIP, atherogenic index of plasma; CTOs, chronic total occlusions; ROC, receiver operating characteristic.

(95% CI: -0.002 to 0.122,  $p = 0.044$ ) and 0.016 (95% CI: -0.039 to 0.183,  $p = 0.761$ ), respectively. The NRI of CTO patients and non-CTO patients were 0.032 (95% CI: -0.018 to 0.054,  $p = 0.083$ ) and 0.034 (95% CI: -0.006 to 0.093,  $p = 0.169$ ), respectively. The NRI of poor and well-formed CCC groups were -0.005 (95% CI: -0.091 to 0.020,  $p = 0.866$ ) and 0.022 (95% CI: -0.017 to 0.224,  $p = 0.740$ ), respectively. The NRI matrix of AIP predicting CTO lesions and poor CCC formation is shown in Figs. 4,5, respectively.

#### 4. Discussion

The present study demonstrated that (1) AIP was significantly higher in the CTOs group compared with the non-



**Fig. 3. AIP prediction of CCC poor formation with ROC curves.** CCC, coronary collateral circulation; ROC, receiver operating characteristic.

CTOs group, (2) AIP of CTOs patients with the poor CCC formation group was significantly higher than that of the good CCC formation group, (3) the AIP was positively associated with a higher prevalence of CTOs and CCC poor formation and (4) AIP is a moderate predictor of CTO and poor CCC formation. According to the above results, AIP may provide some assistance in the diagnosis, prognosis, and risk assessment of CTO patients. AIP may also provide some value for judging the poor formation of CCC in CTO patients. The area under the ROC of AIP detection of CTO patients and poor CCC formation is less than 0.7, which means that AIP is only a moderate indicator of CTO and poor CCC formation. This differs from previous findings,

**Table 2. Basic clinical characteristics of CTOs patients.**

| Variables                | Good CCC formation group (n = 139) | Poor CCC formation group (n = 206) | p value             |
|--------------------------|------------------------------------|------------------------------------|---------------------|
| Age                      | 63.30 ± 10.80                      | 61.46 ± 12.10                      | <0.001 <sup>1</sup> |
| Gender [man (%)]         | 120 (42.0)                         | 166 (58.0)                         | 0.190               |
| Smoking                  | 68 (41.2)                          | 97 (58.8)                          | 0.743               |
| Diabetes                 | 38 (38.4)                          | 61 (61.6)                          | 0.716               |
| Hypertension             | 92 (43.4)                          | 120 (56.6)                         | 0.144               |
| TC (mmol/L)              | 4.31 ± 0.90                        | 4.59 ± 1.12                        | 0.010 <sup>2</sup>  |
| TG (mmol/L)              | 1.45 (1.01, 2.07)                  | 1.51 (1.06, 2.24)                  | 0.081               |
| HDL (mmol/L)             | 1.06 ± 0.30                        | 0.98 ± 0.24                        | 0.010 <sup>1</sup>  |
| LDL (mmol/L)             | 2.69 ± 0.71                        | 2.86 ± 0.85                        | 0.048 <sup>2</sup>  |
| LP(a) (mg/L)             | 109.95 (53.53, 210.63)             | 127.70 (65.40, 243.65)             | 0.011 <sup>2</sup>  |
| AIP                      | 1.37 (0.84, 2.13)                  | 1.73 (1.12, 2.90)                  | 0.002 <sup>1</sup>  |
| Occlusive vessel (%)     |                                    |                                    |                     |
| Multiple vessels lesions | 31 (63.3)                          | 18 (36.7)                          | 0.001 <sup>1</sup>  |
| LAD                      | 37 (37.4)                          | 62 (62.6)                          | 0.544               |
| LCX                      | 19 (27.1)                          | 51 (72.9)                          | 0.014 <sup>2</sup>  |
| RCA                      | 52 (40.9)                          | 75 (59.1)                          | 0.909               |

CTOs, chronic total occlusions; CCC, coronary collateral circulation; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LP(a), Lipoprotein(a); LAD, left anterior descending artery; AIP, atherogenic index of plasma; RCA, right coronary artery; LCX, left circumflex artery.

Note: <sup>1</sup>*p* < 0.01, <sup>2</sup>*p* < 0.05.

**Table 3. Logistic regression analysis of CTOs risk factors.**

| Variables    | B      | Wald   | OR    | 95% CI      | p value |
|--------------|--------|--------|-------|-------------|---------|
| Age          | 0.052  | 44.151 | 1.053 | 1.037–1.069 | <0.001  |
| Sex          | –1.374 | 46.014 | 0.253 | 0.170–1.069 | <0.001  |
| Smoking      | 0.849  | 22.374 | 2.337 | 1.644–3.323 | <0.001  |
| Diabetes     | 0.875  | 19.100 | 2.399 | 1.620–3.551 | <0.001  |
| Hypertension | 0.481  | 8.990  | 1.618 | 1.181–2.217 | 0.003   |
| TC (mmol/L)  | –0.369 | 5.547  | 0.692 | 0.509–0.940 | 0.019   |
| LDL (mmol/L) | 0.557  | 8.627  | 1.746 | 1.204–2.532 | 0.003   |
| Lp(a) (mg/L) | 0.001  | 7.420  | 1.001 | 1.000–1.002 | 0.006   |
| AIP          | 1.475  | 24.455 | 4.371 | 2.436–7.844 | <0.001  |

OR, odds ratio; CI, confidence interval; TC, total cholesterol; CTOs, chronic total occlusions; LDL, low-density lipoprotein; LP(a), Lipoprotein(a); AIP, atherogenic index of plasma.

possibly due to the characteristics of observational studies and the relatively small sample size of this study.

CTO is one of the leading causes of death in CAD patients because of its complexity and operating procedure difficulty. A well-developed CCC could have a favorable impact on outcomes and functions for CTOs patients. Studies have shown that CCC formation could play an important role in reducing mortality, recurrence of myocardial infarction, MACE and improving the overall prognosis of patients [20–22]. While CCC formation is involved in disorders of metabolism, evidence has shown that CCC formation is associated with diabetes, metabolic syndrome, and dyslipidemia. The underlying factors contributing to this association may involve endothelial and smooth muscle cell dysfunction, as well as inflammatory cells and cytokines caused by the hostile metabolic environment [3,23].

Dyslipidemia is traditionally a contributing factor to CAD. Current studies revealed that elevated plasma levels of TG and low plasma concentrations of HDL-C are closely associated with a high risk of CAD, even at or below recommended LDL-C goals [24,25]. Experimental evidence showed that TG and HDL-C play a role in the pathophysiology of atherothrombosis. TG may provoke atherogenesis by upregulating the production of pro-inflammatory cytokines and enhancing inflammatory response and cell activation [26,27]. In addition, the elevation of TG could stimulate the secretion of tissue factors from endothelial cells and monocytes, and are related to an increase of fibrinogen and coagulation factors in the plasma [28,29]. A study suggested that TG could directly contribute to plaque formation and progression [30]. The functionality of HDL is relevant to atheroprotective effects, including anti-inflammatory




**Table 4. Logistic regression analysis of CCC formation risk factors.**

| Variables    | B      | Wald   | OR    | 95% CI      | <i>p</i> value |
|--------------|--------|--------|-------|-------------|----------------|
| Age          | 0.000  | 0.001  | 1.000 | 0.978–1.023 | 0.970          |
| Sex          | 0.461  | 1.764  | 1.585 | 0.803–3.130 | 0.184          |
| Smoking      | −0.074 | 0.082  | 0.928 | 0.559–1.543 | 0.775          |
| Diabetes     | 0.032  | 0.015  | 1.033 | 0.615–1.734 | 0.903          |
| Hypertension | −0.411 | 2.767  | 0.663 | 0.408–1.076 | 0.096          |
| Multivessel  | −1.183 | 12.519 | 0.306 | 0.159–0.590 | 0.001          |
| TC (mmol/L)  | −0.005 | 0.000  | 0.995 | 0.621–1.595 | 0.984          |
| LDL (mmol/L) | 0.330  | 1.134  | 1.391 | 0.758–2.556 | 0.287          |
| Lp(a) (mg/L) | −0.001 | 2.610  | 0.999 | 0.998–1.000 | 0.106          |
| AIP          | 1.303  | 7.978  | 3.680 | 1.490–9.090 | 0.005          |

OR, odds ratio; CI, confidence interval; TC, total cholesterol; LDL, low-density lipoprotein; LP(a), Lipoprotein(a); CCC, coronary collateral circulation; AIP, atherogenic index of plasma.

### NRI matrix of AIP predicting CTO lesions




**Fig. 4. NRI matrix of AIP predicting CTO lesions.** NRI, net reclassification index; AIP, atherogenic index of plasma; CTO, chronic total occlusive; CCC, coronary collateral circulation.

and anti-thrombotic activities, anti-apoptosis of endothelial cells, and anti-oxidative stress in the process of atherosclerosis [31]. HDL facilitates cholesterol efflux from lipid-rich macrophages within atherosclerotic plaques in the arterial walls. This efflux is mediated by the interactions of apolipoprotein A-I (apoA-I) with adenosine triphosphate-binding cassette transporter A1 (ABCA1). The cholesterol is then transported to the liver for metabolism or biliary excretion [32]. Furthermore, HDL has anti-inflammatory and anti-oxidative effects by regulating endothelial homeostasis and anti-thrombus through attenuation of platelet aggregation and adhesion responses [33]. Thus, it seems more reasonable to use AIP to predict CTOs and CCC formation, since this index represents the ratio of atherosclerosis par-

ticles to anti-atherosclerosis particles in the plasma. These protective mechanisms could be related to endothelial function and inflammation in the atherosclerosis process.

The AIP is determined by the logarithmic transformation of the ratio of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C). Many studies have focused on the relationship between AIP and CAD risk. Previous research links AIP to obesity, hypertension, diabetes, and metabolic syndrome [34]. A study also found that AIP was significantly higher in CAD patients compared with healthy individuals [35], and that AIP was associated with the severity of acute coronary syndrome in young adults [36]. In another study [6], AIP was an independent risk factor for CAD and a higher SYNTAX score  $\geq 23$  (OR = 1.623,



**Fig. 5. NRI matrix of AIP predicting CCC poor formation.** NRI, net reclassification index; AIP, atherogenic index of plasma; CCC, coronary collateral circulation; CTO, chronic total occlusion.

95% CI: 1.118–2.358,  $p < 0.01$ ). When the AIP is 2.23, patients may have a higher risk of severe coronary atherosclerosis. Guelker *et al.* [7] found that AIP could predict the complexity of percutaneous coronary intervention (PCI) of CTOs. A higher AIP correlated with a higher J-CTO score, representing the complexity of CTO lesions. AIP was positively related to longer occlusions, longer stent coverage, and a higher number of implanted stents in CTO patients [7]. In this study, AIP was significantly elevated in the CTOs group compared to the non-CTOs group. This result is consistent with another study [2], which also found AIP was positively correlated with the Thrombolysis in Myocardial Infarction (TIMI) score and the Gensini score, when AIP was 0.345, the specificity of the AIP to diagnose CTO was 78.2% and the sensitivity was 65.6%, and that AIP is independently correlated with CTO (OR = 7.024, 95% CI: 5.268–9.365). While the present study showed that AIP was negatively correlated with the Rentrop grade, and that AIP could not only predict the CTOs, with 74.7% specificity, but also predict the CCC formation in CTOs, with a 92.2% sensitivity. The result also showed that AIP was an independent risk factor for CTOs (OR = 3.199, 95% CI: 1.911–5.357) and poor CCC formation (OR = 3.749, 95% CI: 1.628–8.635). However, according to our findings, AIP is only a moderate indicator of CTO and poor CCC formation.

Our study has several limitations. First, all the data in this study were collected from a single hospital and analyzed retrospectively. Therefore, the data could be influenced by measurements, operators, and techniques, and se-

lection bias could exist. Second, we used coronary angiography to evaluate CCC and Rentrop grade, the accuracy of which is far lower than other methods (e.g., CFI). The catheter size and the spatial resolution of the angiography system could have affected the results of the Rentrop grade in this study. Finally, the present study did not completely demonstrate the underlying mechanism between AIP and CCC formation in CTOs patients.

## 5. Conclusions

AIP was significantly higher in the CTOs group and the poor CCC formation group compared with the non-CTOs group and good CCC formation group. We found that AIP was positively correlated with the increased risk of CTOs and poor CCC formation. We found AIP to be a moderate but not powerful indicator for detecting both CTO patients and poor CCC formation. AIP may be used as a noninvasive biomarker to evaluate CTOs and poor CCC formation in clinical practice.

## Abbreviations

AIP, atherogenic index of plasma; CAD, coronary artery disease; CTOs, Chronic total occlusions; CCC, coronary collateral circulation; ROC, Receiver operating characteristic; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, nonhigh-density lipoprotein cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LP(a), Lipoprotein(a); CI, confidence interval; LAD, left anterior descending artery; LCA, left circumflex artery; RCA, right coronary artery; CFI, Collateral Flow Index;

MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention; J-CTO score, Japanese Multicenter CTO Registry score; TIMI, Thrombolysis in Myocardial Infarction.

## Availability of Data and Materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

## Author Contributions

YL, YF, and YZ designed the research and drafted the manuscript. YL, YF, SL, JL and PF collected the data and helped implement and analyze the research. YZ, MZ and JW interpreted the data and reviewed the results, revised the manuscript, and confirmed the final published version. All of the authors read and approved the final manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

## Ethics Approval and Consent to Participate

The study protocol was approved by the Ethics Committee of the Zhongnan Hospital of Wuhan University (ethics number: 2023079K) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was also waived because of the retrospective and observational nature of the study. We have de-identified all patient details to ensure they cannot be identified.

## Acknowledgment

Thanks to all the members of the research group and friends who have helped us in this process.

## Funding

This study was supported by the Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University (grant number ZNJC202201).

## Conflict of Interest

The authors declare no conflict of interest.

## Supplementary Material

Supplementary material associated with this article can be found, in the online version, at <https://doi.org/10.31083/j.rcm2410305>.

## References

[1] Kahn JK. Angiographic Suitability for Catheter Revascularization of Total Coronary Occlusions in Patients from A Community Hospital Setting. *American Heart Journal*. 1993; 126: 561–564.

- [2] Liu T, Liu J, Wu Z, Lv Y, Li W. Predictive Value of The Atherogenic Index of Plasma for Chronic Total occlusion before Coronary Angiography. *Clinical Cardiology*. 2021; 44: 518–525.
- [3] Jamaiyar A, Juguilon C, Dong F, Cumpston D, Enrick M, Chilian WM, *et al*. Cardioprotection During Ischemia by Coronary Collateral Growth. *American Journal of Physiology-Heart and Circulatory Physiology*. 2019; 316: H1–H9.
- [4] Vo MN, Brilakis ES, Kass M, Ravandi A. Physiologic Significance of Coronary Collaterals in Chronic Total Occlusions. *Canadian Journal of Physiology and Pharmacology*. 2015; 93: 867–871.
- [5] Meier P, Schirmer SH, Lansky AJ, Timmis A, Pitt B, Seiler C. The Collateral Circulation of The Heart. *BMC Medicine*. 2013; 11: 143.
- [6] Wang L, Chen F, Xiaoqi C, Yujun C, Zijie L. Atherogenic Index of Plasma is an Independent Risk Factor for Coronary Artery Disease and a Higher SYNTAX Score. *Angiology*. 2021; 72: 181–186.
- [7] Guelker JE, Bufe A, Blockhaus C, Kroeger K, Rock T, Akin I, *et al*. The Atherogenic Index of Plasma and Its Impact on Recanalization of Chronic total occlusion. *Cardiology Journal*. 2020; 27: 756–761.
- [8] Sianos G, Werner GS, Galassi AR, Papafaklis MI, Escaned J, Hildick-Smith D, *et al*. Recanalisation of Chronic Total Coronary Occlusions: 2012 Consensus Document from the EuroCTO club. *EuroIntervention*. 2012; 8: 139–145.
- [9] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *The Lancet*. 2007; 370: 1453–1457.
- [10] Peter Rentrop K, Cohen M, Blanke H, Phillips RA. Changes in Collateral Channel Filling Immediately after Controlled Coronary Artery Occlusion by an Angioplasty Balloon in Human Subjects. *Journal of the American College of Cardiology*. 1985; 5: 587–592.
- [11] Koelbl CO, Nedeljkovic ZS, Jacobs AK. Coronary Chronic Total Occlusion (CTO): a Review. *Reviews in Cardiovascular Medicine*. 2018; 19: 33–39.
- [12] Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Oshero AB, Yalonetsky S, *et al*. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. *Journal of the American College of Cardiology*. 2012; 59: 991–997.
- [13] Wolff R, Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Sparkes JD, *et al*. Gender Differences in the Prevalence and Treatment of Coronary Chronic Total Occlusions. *Catheterization and Cardiovascular Interventions*. 2016; 87: 1063–1070.
- [14] Chen X, Lin Y, Tian L, Wang Z. Correlation Between Ischemia-modified Albumin Level and Coronary Collateral Circulation. *BMC Cardiovascular Disorders*. 2020; 20: 326.
- [15] Mares A, Mukherjee D. Management of Chronic Total Occlusion of Coronary Artery. *International Journal of Angiology*. 2021; 30: 48–52.
- [16] Allahwala UK, Kiat H, Ekmejian A, Mughal N, Bassin L, Ward M, *et al*. Both Surgical and Percutaneous Revascularization Improve Prognosis in Patients with a Coronary Chronic Total Occlusion (CTO) Irrespective of Collateral Robustness. *Heart and Vessels*. 2021; 36: 1653–1660.
- [17] Shokry KA, Farag EM, Salem AMH, Abdelaziz M, El-Zayat A, Ibrahim IM. Relationship Between Quality of Coronary Collateral and Myocardial Viability in Chronic Total Occlusion: a Magnetic Resonance Study. *The International Journal of Cardiovascular Imaging*. 2021; 37: 623–631.
- [18] Dong W, Li J, Mi H, Song X, Jiao J, Li Q. Relationship Between Collateral Circulation and Myocardial Viability of 18F-



- FDG PET/CT Subtended by Chronic Total Occluded Coronary Arteries. *Annals of Nuclear Medicine*. 2018; 32: 197–205.
- [19] Celik T, Celik M, Iyisoy A. Coronary collateral circulation. *Turk Kardiyoloji Dernegi Arsivi*. 2010; 38: 505–514. (In Turkish)
- [20] Seiler C, Engler R, Berner L, Stoller M, Meier P, Steck H, *et al*. Prognostic Relevance of Coronary Collateral Function: Confounded or Causal Relationship? *Heart*. 2013; 99: 1408–1414.
- [21] Meier P, Hemingway H, Lansky AJ, Knapp G, Pitt B, Seiler C. The Impact of the Coronary Collateral Circulation on Mortality: a Meta-analysis. *European Heart Journal*. 2012; 33: 614–621.
- [22] Seiler C, Stoller M, Pitt B, Meier P. The Human Coronary Collateral Circulation: Development and Clinical Importance. *European Heart Journal*. 2013; 34: 2674–2682.
- [23] Duan J, Murohara T, Ikeda H, Katoh A, Shintani S, Sasaki K, *et al*. Hypercholesterolemia Inhibits Angiogenesis in Response to Hindlimb Ischemia: Nitric Oxide-dependent Mechanism. *Circulation*. 2000; 102: III370–III376.
- [24] Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol after Acute Coronary Syndrome in the PROVE it-TIMI 22 Trial. *Journal of the American College of Cardiology*. 2008; 51: 724–730.
- [25] Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, *et al*. HDL Cholesterol, very Low Levels of LDL Cholesterol, and Cardiovascular Events. *New England Journal of Medicine*. 2007; 357: 1301–1310.
- [26] Giannattasio C, Zoppo A, Gentile G, Failla M, Capra A, Maggi FM, *et al*. Acute Effect of High-Fat Meal on Endothelial Function in Moderately Dyslipidemic Subjects. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2005; 25: 406–410.
- [27] Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, Rutledge JC. Triglyceride-rich Lipoprotein Lipolysis Releases Neutral and Oxidized FFAs that Induce Endothelial Cell Inflammation. *Journal of Lipid Research*. 2009; 50: 204–213.
- [28] Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, *et al*. Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity. *Circulation*. 2003; 107: 973–977.
- [29] Grant PJ. Diabetes Mellitus as a Prothrombotic Condition. *Journal of Internal Medicine*. 2007; 262: 157–172.
- [30] Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. *Circulation*. 2002; 106: 2137–2142.
- [31] Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, *et al*. Triglyceride-rich Lipoproteins and High-density Lipoprotein Cholesterol in Patients at High Risk of Cardiovascular Disease: Evidence and Guidance for Management. *European Heart Journal*. 2011; 32: 1345–1361.
- [32] Annema W, von Eckardstein A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. *Circulation Journal*. 2013; 77: 2432–2448.
- [33] Wong NKP, Nicholls SJ, Tan JTM, Bursill CA. The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. *International Journal of Molecular Sciences*. 2018; 19: 1680.
- [34] Zhu X, Yu L, Zhou H, Ma Q, Zhou X, Lei T, *et al*. Atherogenic Index of Plasma is a Novel and Better Biomarker Associated with Obesity: a Population-based Cross-sectional Study in China. *Lipids in Health and Disease*. 2018; 17: 37.
- [35] Cai G, Shi G, Xue S, Lu W. The Atherogenic Index of Plasma is a Strong and Independent Predictor for Coronary Artery Disease in the Chinese Han Population. *Medicine*. 2017; 96: e8058.
- [36] Cai G, Liu W, Lv S, Wang X, Guo Y, Yan Z, *et al*. Gender-specific Associations Between Atherogenic Index of Plasma and the Presence and Severity of Acute Coronary Syndrome in very Young Adults: a Hospital-based Observational Study. *Lipids in Health and Disease*. 2019; 18: 99.